September 25, 2008

EDAP’s Ablatherm-HIFU Technology Featured At City of Hope Second Annual Conference On New Technologies and Innovative Treatment Strategies for Genitourinary Malignancies

LYON, France, Sept. 25, 2008 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that its High Intensity Focused Ultrasound (HIFU) technology was highlighted at the City of Hope Second Annual Conference on New Technologies and Innovative Treatment Strategies for Genitourinary Malignancies from September 12-14, 2008 in San Diego, California.

Douglas Chinn, MD of Chinn & Chinn Urology Medical Associates in Arcadia, California, discussed EDAP's minimally invasive ultrasound technology in a presentation entitled "HIFU: Should It be Approved by the FDA?" His discussion was part of the three-day multidisciplinary symposium featuring recent advances in the diagnosis and treatment of cancers of the kidney, testis, bladder and prostate.

Douglas Chinn, MD commented, "My presentation provided information to raise awareness of HIFU and other modalities for the treatment of prostate cancer among urologists who primarily rely on robotic urologic surgery to address the disease. This lecture also reviewed the FDA process and appropriate pathway for patient access to HIFU technology via an ongoing FDA approved Phase II/III clinical trial."

Marc Oczachowski, EDAP's Chief Executive Officer, said, "City of Hope's meeting provided EDAP with a unique opportunity to educate urologists about our minimally invasive HIFU technology for the treatment of localized prostate cancer. While many of the urologists at the event are accustomed to robotic urologic surgery, Dr. Chinn highlighted the benefits of HIFU as a safe and viable treatment alternative. The event provided us with an excellent forum to showcase the advantages of our non-invasive ultrasound treatment. We continued to be successful in increasing the awareness and adoption of our products by presenting extensive clinical results and participating in peer-to-peer interactions among urologists discussing Ablatherm-HIFU's proven technology."

About City of Hope

City of Hope is a leading research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a Comprehensive Cancer Center, the highest honor bestowed by the National Cancer Institute, and a founding member of the National Comprehensive Cancer Network, City of Hope's research and treatment protocols advance care throughout the nation. City of Hope is located in Duarte, Calif., just northeast of Los Angeles, and is ranked as one of "America's Best Hospitals" in cancer and urology by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics.


EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit, and or

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

This news release was distributed by GlobeNewswire,

 CONTACT:  EDAP TMS SA           Investor Relations/Legal Affairs:           Blandine Confort           +33 4 72 15 31 72           [email protected]              The Ruth Group           Investors:           R.J. Pellegrino           646-536-7009           [email protected]com